|
|
|
|
Friday, February 14, 2020
Trovagene (TROV)
Lead Drug Shows Efficacy in Difficult to Treat Prostate Cancer Patients
Trovagene, Inc. is a clinical stage biotechnology company focused on the development of new therapeutics for hematology and oncology. The company’s clinical programs of Onvansertib (PLK1 inhibitor) include Phase 1b/2 study in AML, Phase 1b/2 study in mCRPC and Phase 1b/2 trial in KRAS-mutant colorectal cancer.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Data Presentation at ASCO Medical Conference. Trovagene, Inc. yesterday announced results from an ongoing Phase II clinical trial on the use of its lead drug, onvansertib, in combination with hormonal therapy for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Results were presented at the American Society for Clinical Oncology (ASCO) 2020 Genitourinary Cancers Symposium in San Francisco.
Patients treated with onvansertib showed a clinical benefit. In the trial, 63% of the evaluable mCRPC patients (12 out of nineteen) treated with onvansertib showed a response to treatment. Patients carrying genetic alterations of the androgen receptor, a very difficult patient population to treat, showed a clinical benefit, which we believe is a…
Get the full report on Channelchek desktop.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst
certification and important disclosures included in the full report.
NOTE: investment decisions should not be based upon the content of
this research summary. Proper due diligence is required before
making any investment decision.